1
|
Petrova M, Vlahova Z, Schröder M, Todorova J, Tzintzarov A, Gospodinov A, Velkova L, Kaynarov D, Dolashki A, Dolashka P, Ugrinova I. Antitumor Activity of Bioactive Compounds from Rapana venosa against Human Breast Cell Lines. Pharmaceuticals (Basel) 2023; 16:181. [PMID: 37259331 PMCID: PMC9959655 DOI: 10.3390/ph16020181] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 01/16/2023] [Accepted: 01/18/2023] [Indexed: 04/12/2024] Open
Abstract
This study is the first report describing the promising antitumor activity of biologically active compounds isolated from the hemolymph of marine snail Rapana venosa-a fraction with Mw between 50 and 100 kDa and two structural subunits (RvH1 and RvH2), tested on a panel of human breast cell lines-six lines of different molecular subtypes of breast cancer MDA-MB-231, MDA-MB-468, BT-474, BT-549, SK-BR-3, and MCF-7 and the non-cancerous MCF-10A. The fraction with Mw 50-100 kDa (HRv 50-100) showed good antitumor activity manifested by a significant decrease in cell viability, altered morphology, autophagy, and p53 activation in treated cancer cells. An apparent synergistic effect was observed for the combination of HRv 50-100 with cis-platin for all tested cell lines. The combination of HRv 50-100 with cisplatin and/or tamoxifen is three times more effective compared to treatment with classical chemotherapeutics alone. The main proteins in the active fraction, with Mw at ~50 kDa, ~65 kDa, ~100 kDa, were identified by MALDI-MS, MS/MS analyses, and bioinformatics. Homology was established with known proteins with antitumor potential detected in different mollusc species: peroxidase-like protein, glycoproteins Aplysianin A, L-amino acid oxidase (LAAO), and the functional unit with Mw 50 kDa of RvH. Our study reveals new perspectives for application of HRv 50-100 as an antitumor agent used alone or as a booster in combination with different chemotherapies.
Collapse
Affiliation(s)
- Maria Petrova
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| | - Zlatina Vlahova
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| | - Maria Schröder
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| | - Jordana Todorova
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| | - Alexander Tzintzarov
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| | - Anastas Gospodinov
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| | - Lyudmila Velkova
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 9, 1113 Sofia, Bulgaria
| | - Dimitar Kaynarov
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 9, 1113 Sofia, Bulgaria
| | - Aleksandar Dolashki
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 9, 1113 Sofia, Bulgaria
| | - Pavlina Dolashka
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 9, 1113 Sofia, Bulgaria
| | - Iva Ugrinova
- Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bld. 21, 1113 Sofia, Bulgaria
| |
Collapse
|
2
|
Manganyi MC, Tlatsana GS, Mokoroane GT, Senna KP, Mohaswa JF, Ntsayagae K, Fri J, Ateba CN. Bulbous Plants Drimia: "A Thin Line between Poisonous and Healing Compounds" with Biological Activities. Pharmaceutics 2021; 13:1385. [PMID: 34575461 PMCID: PMC8465487 DOI: 10.3390/pharmaceutics13091385] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 07/26/2021] [Accepted: 07/28/2021] [Indexed: 11/18/2022] Open
Abstract
Drimia (synonym Urginea) plants are bulbous plants belonging to the family Asparagaceae (formerly the family Hyacinthaceae) and are distinctive, powerful medicinal plants. Just some species are indigenous to South Africa and have been traditionally utilized for centuries to cure various diseases and/or ailments. They have been recognized among the most famous and used medicinal plants in South Africa. Traditionally, the plants are used for various illnesses such as dropsy, respiratory disease, bone and joint complications, skin disorders, epilepsy and cancer. A number of studies have reported biological properties such as antiviral, antibacterial, antioxidant and anti-inflammatory, immunomodulatory, and anticancer activities. Their bulbs are a popular treatment for colds, measles, pneumonia, coughs, fever and headaches. However, some plant species are regarded as one of the six most common poisonous plants in Southern Africa that are toxic to livestock and humans. Due to the therapeutic effects of the Drimia plant bulb, research has focused on the phytochemicals of Drimia species. The principal constituents isolated from this genus are cardiac glycosides. In addition, phenolic compounds, phytosterols and other phytochemical constituents were identified. This study constitutes a critical review of Drimia species' bioactive compounds, toxicology, biological properties and phytochemistry, advocating it as an important source for effective therapeutic medicine. For this purpose, various scientific electronic databases such as ScienceDirect, Scopus, Google Scholar, PubMed and Web of Science were researched and reviewed to conduct this study. Despite well-studied biological investigations, there is limited research on the toxic properties and the toxic compounds of certain Drimia species. Searching from 2017 to 2021, Google Scholar search tools retrieved 462 publications; however, only 3 investigated the toxicity and safety aspects of Drimia. The aim was to identify the current scientific research gap on Drimia species, hence highlighting a thin line between poisonous and healing compounds, dotted across numerous publications, in this review paper.
Collapse
Affiliation(s)
- Madira Coutlyne Manganyi
- Department of Biological and Environmental Sciences, Faculty of Natural Sciences, Walter Sisulu University, PBX1, Mthatha 5117, South Africa
| | - Gothusaone Simon Tlatsana
- Department of Microbiology, Mafikeng Campus, North West University, Mmabatho 2735, South Africa; (G.S.T.); (G.T.M.); (K.P.S.); (J.F.M.); (K.N.); (J.F.)
| | - Given Thato Mokoroane
- Department of Microbiology, Mafikeng Campus, North West University, Mmabatho 2735, South Africa; (G.S.T.); (G.T.M.); (K.P.S.); (J.F.M.); (K.N.); (J.F.)
| | - Keamogetswe Prudence Senna
- Department of Microbiology, Mafikeng Campus, North West University, Mmabatho 2735, South Africa; (G.S.T.); (G.T.M.); (K.P.S.); (J.F.M.); (K.N.); (J.F.)
| | - John Frederick Mohaswa
- Department of Microbiology, Mafikeng Campus, North West University, Mmabatho 2735, South Africa; (G.S.T.); (G.T.M.); (K.P.S.); (J.F.M.); (K.N.); (J.F.)
| | - Kabo Ntsayagae
- Department of Microbiology, Mafikeng Campus, North West University, Mmabatho 2735, South Africa; (G.S.T.); (G.T.M.); (K.P.S.); (J.F.M.); (K.N.); (J.F.)
| | - Justine Fri
- Department of Microbiology, Mafikeng Campus, North West University, Mmabatho 2735, South Africa; (G.S.T.); (G.T.M.); (K.P.S.); (J.F.M.); (K.N.); (J.F.)
| | - Collins Njie Ateba
- Food Security and Safety Niche Area, Faculty of Natural and Agricultural Sciences, North-West University, Mmabatho 2735, South Africa;
| |
Collapse
|
3
|
Boniface PK, Elizabeth FI. Flavones as a Privileged Scaffold in Drug Discovery: Current Developments. Curr Org Synth 2020; 16:968-1001. [PMID: 31984880 DOI: 10.2174/1570179416666190719125730] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 04/03/2019] [Accepted: 04/27/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Flavones are one of the main subclasses of flavonoids with diverse pharmacological properties. They have been reported to possess antimalarial, antimicrobial, anti-tuberculosis, anti-allergic, antioxidant, anti-inflammatory activities, among others. OBJECTIVE The present review summarizes the recent information on the pharmacological properties of naturally occurring and synthetic flavones. METHODS Scientific publications referring to natural and synthetic flavones in relation to their biological activities were hand-searched in databases such as SciFinder, PubMed (National Library of Medicine), Science Direct, Wiley, ACS, SciELO, Springer, among others. RESULTS As per the literature, seventy-five natural flavones were predicted as active compounds with reference to their IC50 (<20 µg/mL) in in vitro studies. Also, synthetic flavones were found active against several diseases. CONCLUSION As per the literature, flavones are important sources for the potential treatment of multifactorial diseases. However, efforts toward the development of flavone-based therapeutic agents are still needed. The appearance of new catalysts and chemical transformations is expected to provide avenues for the synthesis of unexplored flavones, leading to the discovery of flavones with new properties and biological activities.
Collapse
Affiliation(s)
- Pone K Boniface
- Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Ferreira I Elizabeth
- Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| |
Collapse
|
4
|
Aswal S, Kumar A, Semwal RB, Chauhan A, Kumar A, Lehmann J, Semwal DK. Drimia indica: A Plant Used in Traditional Medicine and Its Potential for Clinical Uses. ACTA ACUST UNITED AC 2019; 55:E255. [PMID: 31181697 DOI: 10.3390/medicina55060255] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 06/05/2019] [Accepted: 06/05/2019] [Indexed: 12/27/2022]
Abstract
Drimia indica (Roxb.) Jessop (Asparagaceae) is a reputed Ayurvedic medicine for a number of therapeutic benefits, including for cardiac diseases, indigestion, asthma, dropsy, rheumatism, leprosy, and skin ailments. The present work aimed to critically and extensively review its traditional uses, phytochemistry, pharmacology, toxicology, and taxonomy together with the mechanisms of action of selected extracts of D. indica. A systematic literature survey from scientific databases such as PubMed, Scopus, and Web of Science as well as from some textbooks and classical texts was conducted. The plant, mainly its bulb, contains various bioactive constituents, such as alkylresorcinols, bufadienolides, phytosterols, and flavonoids. Various scientific studies have proven that the plant has anthelmintic, anticancer, antidiabetic, antimicrobial, antioxidant, and wound healing activities. The present work concludes that D. indica has the potential to treat various diseases, mainly microbial infections. This review also suggests that bufadienolides, flavonoids, and steroids might be responsible for its bioactive potential.
Collapse
|